Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 417


Growth hormone in the tumor microenvironment.

Chesnokova V, Melmed S.

Arch Endocrinol Metab. 2019 Nov-Dec;63(6):568-575. doi: 10.20945/2359-3997000000186. Review.


The tale in evolution: clarity, consistency and consultation, not contradiction and confusion.

Ho KKY, Fleseriu M, Wass J, van der Lely A, Barkan A, Giustina A, Casanueva FF, Heaney AP, Biermasz N, Strasburger C, Melmed S.

Pituitary. 2020 Jan 7. doi: 10.1007/s11102-019-01027-w. [Epub ahead of print] No abstract available.


Author Correction: Acromegaly.

Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Pereira AM, Pivonello R.

Nat Rev Dis Primers. 2019 Oct 21;5(1):72. doi: 10.1038/s41572-019-0129-5.


A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update.

Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C, Bolanowski M, Bonert V, Bronstein MD, Casanueva FF, Clemmons D, Colao A, Ferone D, Fleseriu M, Frara S, Gadelha MR, Ghigo E, Gurnell M, Heaney AP, Ho K, Ioachimescu A, Katznelson L, Kelestimur F, Kopchick J, Krsek M, Lamberts S, Losa M, Luger A, Maffei P, Marazuela M, Mazziotti G, Mercado M, Mortini P, Neggers S, Pereira AM, Petersenn S, Puig-Domingo M, Salvatori R, Shimon I, Strasburger C, Tsagarakis S, van der Lely AJ, Wass J, Zatelli MC, Melmed S.

J Clin Endocrinol Metab. 2019 Oct 13. pii: dgz096. doi: 10.1210/clinem/dgz096. [Epub ahead of print]


A tale of pituitary adenomas: to NET or not to NET : Pituitary Society position statement.

Ho KKY, Fleseriu M, Wass J, van der Lely A, Barkan A, Giustina A, Casanueva FF, Heaney AP, Biermasz N, Strasburger C, Melmed S.

Pituitary. 2019 Dec;22(6):569-573. doi: 10.1007/s11102-019-00988-2. Review. No abstract available.


Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT® validation study.

Giustina A, Bronstein MD, Chanson P, Petersenn S, Casanueva FF, Sert C, Houchard A, Melmed S.

Pituitary. 2019 Oct;22(5):476-487. doi: 10.1007/s11102-019-00977-5.


Pathogenesis and Diagnosis of Growth Hormone Deficiency in Adults.

Melmed S.

N Engl J Med. 2019 Jun 27;380(26):2551-2562. doi: 10.1056/NEJMra1817346. Review. No abstract available.


Growth Hormone Induces Colon DNA Damage Independent of IGF-1.

Chesnokova V, Zonis S, Barrett RJ, Gleeson JP, Melmed S.

Endocrinology. 2019 Jun 1;160(6):1439-1447. doi: 10.1210/en.2019-00132.



Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Pereira AM, Pivonello R.

Nat Rev Dis Primers. 2019 Mar 21;5(1):20. doi: 10.1038/s41572-019-0071-6. Review. Erratum in: Nat Rev Dis Primers. 2019 Oct 21;5(1):72.


Excess growth hormone suppresses DNA damage repair in epithelial cells.

Chesnokova V, Zonis S, Barrett R, Kameda H, Wawrowsky K, Ben-Shlomo A, Yamamoto M, Gleeson J, Bresee C, Gorbunova V, Melmed S.

JCI Insight. 2019 Feb 7;4(3). pii: 125762. doi: 10.1172/jci.insight.125762. [Epub ahead of print]


Proton Sensitivity of Corticotropin-Releasing Hormone Receptor 1 Signaling to Proopiomelanocortin in Male Mice.

Kameda H, Yamamoto M, Tone Y, Tone M, Melmed S.

Endocrinology. 2019 Feb 1;160(2):276-291. doi: 10.1210/en.2018-00920.


Somatostatin receptor subtype 5 modifies hypothalamic-pituitary-adrenal axis stress function.

Yamamoto M, Ben-Shlomo A, Kameda H, Fukuoka H, Deng N, Ding Y, Melmed S.

JCI Insight. 2018 Oct 4;3(19). pii: 122932. doi: 10.1172/jci.insight.122932.


Correction to: Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement.

Casanueva FF, Barkan AL, Buchfelder M, Klibanski A, Laws ER, Loeffler JS, Melmed S, Mortini P, Wass J, Giustina A; Pituitary Society, Expert Group on Pituitary Tumors.

Pituitary. 2018 Dec;21(6):663. doi: 10.1007/s11102-018-0912-4.


International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Günther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, Lupp A, Korbonits M, Castaño JP, Wester HJ, Culler M, Melmed S, Schulz S.

Pharmacol Rev. 2018 Oct;70(4):763-835. doi: 10.1124/pr.117.015388. Review.



Labadzhyan A, Kim SM, Rhyu J, Araki T, Mahtabifard A, Melmed S.

AACE Clin Case Rep. 2018 Sep-Oct;4(5):e375-e378. doi: 10.4158/ACCR-2018-0045. Epub 2018 May 1.


A Consensus Statement on acromegaly therapeutic outcomes.

Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, Strasburger CJ, Luger A, Clemmons DR, Giustina A.

Nat Rev Endocrinol. 2018 Sep;14(9):552-561. doi: 10.1038/s41574-018-0058-5. Review.


Altered Pituitary Gland Structure and Function in Posttraumatic Stress Disorder.

Cooper O, Bonert V, Moser F, Mirocha J, Melmed S.

J Endocr Soc. 2017 Apr 13;1(6):577-587. doi: 10.1210/js.2017-00069. eCollection 2017 Jun 1.


EGFR Induces E2F1-Mediated Corticotroph Tumorigenesis.

Araki T, Liu X, Kameda H, Tone Y, Fukuoka H, Tone M, Melmed S.

J Endocr Soc. 2017 Jan 20;1(2):127-143. doi: 10.1210/js.2016-1053. eCollection 2017 Feb 1.


Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement.

Casanueva FF, Barkan AL, Buchfelder M, Klibanski A, Laws ER, Loeffler JS, Melmed S, Mortini P, Wass J, Giustina A; Pituitary Society, Expert Group on Pituitary Tumors.

Pituitary. 2017 Oct;20(5):489-498. doi: 10.1007/s11102-017-0838-2. Erratum in: Pituitary. 2018 Sep 20;:.


Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells.

Recouvreux MV, Wu JB, Gao AC, Zonis S, Chesnokova V, Bhowmick N, Chung LW, Melmed S.

Endocrinology. 2017 Jul 1;158(7):2255-2268. doi: 10.1210/en.2016-1939.


Melvin M. Grumbach 1925-2016.

Melmed S.

Proc Natl Acad Sci U S A. 2017 May 9;114(19):4845-4847. doi: 10.1073/pnas.1705693114. Epub 2017 Apr 24. No abstract available.


Long-Term Endocrine Outcomes Following Endoscopic Endonasal Transsphenoidal Surgery for Acromegaly and Associated Prognostic Factors.

Babu H, Ortega A, Nuno M, Dehghan A, Schweitzer A, Bonert HV, Carmichael JD, Cooper O, Melmed S, Mamelak AN.

Neurosurgery. 2017 Aug 1;81(2):357-366. doi: 10.1093/neuros/nyx020.


E2F1-mediated human POMC expression in ectopic Cushing's syndrome.

Araki T, Liu NA, Tone Y, Cuevas-Ramos D, Heltsley R, Tone M, Melmed S.

Endocr Relat Cancer. 2016 Nov;23(11):857-870. Epub 2016 Oct 7.


Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas.

Ben-Shlomo A, Liu NA, Melmed S.

Pituitary. 2017 Feb;20(1):93-99. doi: 10.1007/s11102-016-0778-2. Review.


Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline.

Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R, Samuels MH.

J Clin Endocrinol Metab. 2016 Nov;101(11):3888-3921. Epub 2016 Oct 13.


Growth hormone is permissive for neoplastic colon growth.

Chesnokova V, Zonis S, Zhou C, Recouvreux MV, Ben-Shlomo A, Araki T, Barrett R, Workman M, Wawrowsky K, Ljubimov VA, Uhart M, Melmed S.

Proc Natl Acad Sci U S A. 2016 Jun 7;113(23):E3250-9. doi: 10.1073/pnas.1600561113. Epub 2016 May 25. Erratum in: Proc Natl Acad Sci U S A. 2016 Aug 30;113(35):E5251.


Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists.

Greenman Y, Cooper O, Yaish I, Robenshtok E, Sagiv N, Jonas-Kimchi T, Yuan X, Gertych A, Shimon I, Ram Z, Melmed S, Stern N.

Eur J Endocrinol. 2016 Jul;175(1):63-72. doi: 10.1530/EJE-16-0206. Epub 2016 May 5.


Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations.

Christiansen JS, Backeljauw PF, Bidlingmaier M, Biller BM, Boguszewski MC, Casanueva FF, Chanson P, Chatelain P, Choong CS, Clemmons DR, Cohen LE, Cohen P, Frystyk J, Grimberg A, Hasegawa Y, Haymond MW, Ho K, Hoffman AR, Holly JM, Horikawa R, Höybye C, Jorgensen JO, Johannsson G, Juul A, Katznelson L, Kopchick JJ, Lee KO, Lee KW, Luo X, Melmed S, Miller BS, Misra M, Popovic V, Rosenfeld RG, Ross J, Ross RJ, Saenger P, Strasburger CJ, Thorner MO, Werner H, Yuen K.

Eur J Endocrinol. 2016 Jun;174(6):C1-8. doi: 10.1530/EJE-16-0111. Epub 2016 Mar 23.


Pituitary Medicine From Discovery to Patient-Focused Outcomes.

Melmed S.

J Clin Endocrinol Metab. 2016 Mar;101(3):769-77. doi: 10.1210/jc.2015-3653. Epub 2016 Feb 23. Review.


New therapeutic agents for acromegaly.

Melmed S.

Nat Rev Endocrinol. 2016 Feb;12(2):90-8. doi: 10.1038/nrendo.2015.196. Epub 2015 Nov 27. Review.


Endocrinology research-reflecting on the past decade and looking to the next.

Herold KC, Majzoub JA, Melmed S, Pendergrass M, Schlumberger M.

Nat Rev Endocrinol. 2015 Nov;11(11):672-80. doi: 10.1038/nrendo.2015.164. Epub 2015 Oct 13. Review.


SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice--development and results from a pilot study.

Giustina A, Bevan JS, Bronstein MD, Casanueva FF, Chanson P, Petersenn S, Thanh XM, Sert C, Houchard A, Guillemin I, Melmed S; SAGIT Investigator Group.

Pituitary. 2016 Feb;19(1):39-49. doi: 10.1007/s11102-015-0681-2.


Fertility and fragrance: another cause of Kallmann syndrome.

Melmed S.

J Clin Invest. 2015 Jun;125(6):2275-8. doi: 10.1172/JCI82061. Epub 2015 May 18.


Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.

Liu NA, Araki T, Cuevas-Ramos D, Hong J, Ben-Shlomo A, Tone Y, Tone M, Melmed S.

J Clin Endocrinol Metab. 2015 Jul;100(7):2557-64. doi: 10.1210/jc.2015-1606. Epub 2015 May 5.


STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion.

Zhou C, Jiao Y, Wang R, Ren SG, Wawrowsky K, Melmed S.

J Clin Invest. 2015 Apr;125(4):1692-702. doi: 10.1172/JCI78173. Epub 2015 Mar 16.


Pituitary tumors.

Melmed S.

Endocrinol Metab Clin North Am. 2015 Mar;44(1):1-9. doi: 10.1016/j.ecl.2014.11.004. Review.


Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial.

Melmed S, Popovic V, Bidlingmaier M, Mercado M, van der Lely AJ, Biermasz N, Bolanowski M, Coculescu M, Schopohl J, Racz K, Glaser B, Goth M, Greenman Y, Trainer P, Mezosi E, Shimon I, Giustina A, Korbonits M, Bronstein MD, Kleinberg D, Teichman S, Gliko-Kabir I, Mamluk R, Haviv A, Strasburger C.

J Clin Endocrinol Metab. 2015 Apr;100(4):1699-708. doi: 10.1210/jc.2014-4113. Epub 2015 Feb 9. Erratum in: J Clin Endocrinol Metab. 2016 Oct;101(10 ):3863.


ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice.

Liu X, Kano M, Araki T, Cooper O, Fukuoka H, Tone Y, Tone M, Melmed S.

Endocrinology. 2015 Jan;156(1):71-9. doi: 10.1210/en.2014-1627.


Acromegaly: assessing the disorder and navigating therapeutic options for treatment.

Melmed S, Kleinberg DL, Bonert V, Fleseriu M.

Endocr Pract. 2014 Oct;20 Suppl 1:7-17; quiz 18-20. doi: 10.4158/EP14430.RA. Review. No abstract available.


Sagit©: A Novel Clinician-Reported Outcome for Managing Acromegaly in Clinical Practice.

Giustina A, Bevan J, Bronstein M, Casanueva F, Chanson P, Petersenn S, Truong TX, Massien C, Dias-Barbosa C, Guillemin I, Arnould B, Melmed S.

Value Health. 2014 Nov;17(7):A355. doi: 10.1016/j.jval.2014.08.754. Epub 2014 Oct 26. No abstract available.


Acromegaly: an endocrine society clinical practice guideline.

Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA; Endocrine Society.

J Clin Endocrinol Metab. 2014 Nov;99(11):3933-51. doi: 10.1210/jc.2014-2700. Epub 2014 Oct 30.


A structural and functional acromegaly classification.

Cuevas-Ramos D, Carmichael JD, Cooper O, Bonert VS, Gertych A, Mamelak AN, Melmed S.

J Clin Endocrinol Metab. 2015 Jan;100(1):122-31. doi: 10.1210/jc.2014-2468.


Endocrine Society 2014 Laureate Awards.

Gustafsson JA, Katzenellenbogen B, Jameson JL, Roth J, Melmed S, McDonnell D, Wartofsky L, Crowley WF Jr, Griz LH, Becker C, Moore DD, Drucker D, Singh N, O'Malley B.

Horm Cancer. 2014 Oct;5(5):339-55. doi: 10.1007/s12672-014-0193-y. No abstract available.


Pituitary tumor-transforming gene 1 regulates the patterning of retinal mosaics.

Keeley PW, Zhou C, Lu L, Williams RW, Melmed S, Reese BE.

Proc Natl Acad Sci U S A. 2014 Jun 24;111(25):9295-300. doi: 10.1073/pnas.1323543111. Epub 2014 Jun 10.


Challenges in life sciences and health systems in the 21st century.

Melmed S, Vari SG.

Croat Med J. 2014 Jun 1;55(3):184-5. No abstract available.


Clinical factors associated with biochemical adrenal-cortisol insufficiency in hospitalized patients.

Ben-Shlomo A, Mirocha J, Gwin SM, Khine AK, Liu NA, Sheinin RC, Melmed S.

Am J Med. 2014 Aug;127(8):754-762. doi: 10.1016/j.amjmed.2014.03.002. Epub 2014 Mar 13.


Constitutive somatostatin receptor subtype-3 signaling suppresses growth hormone synthesis.

Eigler T, Ben-Shlomo A, Zhou C, Khalafi R, Ren SG, Melmed S.

Mol Endocrinol. 2014 Apr;28(4):554-64. doi: 10.1210/me.2013-1327. Epub 2014 Feb 25.


Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis.

Carmichael JD, Bonert VS, Nuño M, Ly D, Melmed S.

J Clin Endocrinol Metab. 2014 May;99(5):1825-33. doi: 10.1210/jc.2013-3757. Epub 2014 Feb 25.


Expert consensus document: A consensus on the medical treatment of acromegaly.

Giustina A, Chanson P, Kleinberg D, Bronstein MD, Clemmons DR, Klibanski A, van der Lely AJ, Strasburger CJ, Lamberts SW, Ho KK, Casanueva FF, Melmed S; Acromegaly Consensus Group.

Nat Rev Endocrinol. 2014 Apr;10(4):243-8. doi: 10.1038/nrendo.2014.21. Epub 2014 Feb 25. Review.


Sca1⁺ murine pituitary adenoma cells show tumor-growth advantage.

Donangelo I, Ren SG, Eigler T, Svendsen C, Melmed S.

Endocr Relat Cancer. 2014 Jan 30;21(2):203-16. doi: 10.1530/ERC-13-0229. Print 2014 Apr.

Supplemental Content

Loading ...
Support Center